Research LetterGermline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Section snippets
Acknowledgements
This study was supported by the National Natural Science Foundation of China (Grant No. 81370073). Fudan University Shanghai Cancer Center Fund (YJJQ201802). Shanghai Rising Star Program (Grant No. 16QA1401100).
References (4)
- et al.
Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide
Eur Urol
(2018) - et al.
Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study
Eur Urol
(2018)
There are more references available in the full text version of this article.
Cited by (0)
© 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.